BREAKWATER: Encorafenib, Cetuximab, and Chemotherapy for Mutant Metastatic Colorectal Cancer | Docwire News
Scott Kopetz, MD, PhD, of MD Anderson Cancer Center, discusses the BREAKWATER study on the use of first-line encorafenib plus cetuximab with or without chemotherapy.